132 related articles for article (PubMed ID: 37982827)
21. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
[TBL] [Abstract][Full Text] [Related]
22. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
Tao Y; Auperin A; Blanchard P; Alfonsi M; Sun XS; Rives M; Pointreau Y; Castelli J; Graff P; Wong Hee Kam S; Thariat J; Veresezan O; Heymann S; Renard-Oldrini S; Lafond C; Cornely A; Casiraghi O; Boisselier P; Lapeyre M; Biau J; Bourhis J
Radiother Oncol; 2020 Sep; 150():18-25. PubMed ID: 32417348
[TBL] [Abstract][Full Text] [Related]
23. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
Ueki Y; Ohshima S; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Ohtaki K; Saijo K; Tanaka R; Togashi T; Sato Y; Takano S; Omata J; Takahashi N; Okabe R; Horii A
Int J Clin Oncol; 2024 Jan; 29(1):20-26. PubMed ID: 37843751
[TBL] [Abstract][Full Text] [Related]
24. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
26. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Gulati S; Desai J; Palackdharry SM; Morris JC; Zhu Z; Jandarov R; Riaz MK; Takiar V; Mierzwa M; Gutkind JS; Molinolo A; Desai PB; Sadraei NH; Wise-Draper TM
Cancer; 2020 Jan; 126(2):354-362. PubMed ID: 31626727
[TBL] [Abstract][Full Text] [Related]
27. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Guigay J; Fayette J; Dillies AF; Sire C; Kerger JN; Tennevet I; Machiels JP; Zanetta S; Pointreau Y; Bozec Le Moal L; Henry S; Schilf A; Bourhis J
Ann Oncol; 2015 Sep; 26(9):1941-1947. PubMed ID: 26109631
[TBL] [Abstract][Full Text] [Related]
28. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH
JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059
[TBL] [Abstract][Full Text] [Related]
29. Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck.
Awan MJ; Nedzi L; Wang D; Tumati V; Sumer B; Xie XJ; Smith I; Truelson J; Hughes R; Myers LL; Lavertu P; Wong S; Yao M
Ann Oncol; 2018 Apr; 29(4):998-1003. PubMed ID: 29346519
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
Day D; Prawira A; Spreafico A; Waldron J; Karithanam R; Giuliani M; Weinreb I; Kim J; Cho J; Hope A; Bayley A; Ringash J; Bratman SV; Jang R; O'Sullivan B; Siu LL; Hansen AR
Oral Oncol; 2020 Sep; 108():104753. PubMed ID: 32464516
[TBL] [Abstract][Full Text] [Related]
31. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
Tao Y; Aupérin A; Sun X; Sire C; Martin L; Coutte A; Lafond C; Miroir J; Liem X; Rolland F; Even C; Nguyen F; Saada E; Maillard A; Colin-Batailhou N; Thariat J; Guigay J; Bourhis J
Eur J Cancer; 2020 Dec; 141():21-29. PubMed ID: 33125944
[TBL] [Abstract][Full Text] [Related]
32. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
[TBL] [Abstract][Full Text] [Related]
33. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
34. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
[TBL] [Abstract][Full Text] [Related]
35. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K
J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723
[TBL] [Abstract][Full Text] [Related]
36. Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax.
Gadsden NJ; Fulcher CD; Li D; Shrivastava N; Thomas C; Segall JE; Prystowsky MB; Schlecht NF; Gavathiotis E; Ow TJ
Mol Cancer Res; 2021 May; 19(5):862-873. PubMed ID: 33495400
[TBL] [Abstract][Full Text] [Related]
37. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
[TBL] [Abstract][Full Text] [Related]
38. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
40. Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy.
Tong CC; Lau KH; Rivera M; Cannan D; Aguirre-Ghiso J; Sikora AG; Gupta V; Forsythe K; Ko EC; Misiukiewicz K; Gurudutt V; Teng MS; Packer SH; Genden EM; Kao J
Oncol Rep; 2012 May; 27(5):1580-6. PubMed ID: 22322320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
